vs
Side-by-side financial comparison of HOPE BANCORP INC (HOPE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $141.0M, roughly 1.3× HOPE BANCORP INC). HOPE BANCORP INC runs the higher net margin — 20.9% vs 1.6%, a 19.3% gap on every dollar of revenue. On growth, HOPE BANCORP INC posted the faster year-over-year revenue change (21.0% vs 5.0%). Over the past eight quarters, HOPE BANCORP INC's revenue compounded faster (9.8% CAGR vs -0.2%).
Bank of Hope is an American bank, based in Los Angeles, that focuses on the Korean American community. The bank was first established on December 30, 1980, under the name Wilshire Bank.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HOPE vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $141.0M | $177.4M |
| Net Profit | $29.5M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 20.9% | 1.6% |
| Revenue YoY | 21.0% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.23 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $141.0M | $177.4M | ||
| Q4 25 | $145.8M | $196.9M | ||
| Q3 25 | $141.9M | $179.5M | ||
| Q2 25 | $94.5M | $181.1M | ||
| Q1 25 | $116.5M | $168.9M | ||
| Q4 24 | $118.0M | $187.3M | ||
| Q3 24 | $116.6M | $168.6M | ||
| Q2 24 | $116.9M | $178.0M |
| Q1 26 | $29.5M | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $30.8M | $5.4M | ||
| Q2 25 | $-24.8M | $-4.8M | ||
| Q1 25 | $21.1M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $24.2M | $-143.5M | ||
| Q2 24 | $25.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 26.8% | 1.2% | ||
| Q3 25 | 25.6% | 3.5% | ||
| Q2 25 | -27.6% | 4.7% | ||
| Q1 25 | 23.9% | 1.2% | ||
| Q4 24 | 25.8% | 13.2% | ||
| Q3 24 | 27.5% | -82.8% | ||
| Q2 24 | 29.5% | 15.9% |
| Q1 26 | 20.9% | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 21.7% | 3.0% | ||
| Q2 25 | -26.2% | -2.7% | ||
| Q1 25 | 18.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 20.7% | -85.1% | ||
| Q2 24 | 21.6% | 10.6% |
| Q1 26 | $0.23 | $0.07 | ||
| Q4 25 | $0.27 | $0.05 | ||
| Q3 25 | $0.24 | $0.12 | ||
| Q2 25 | $-0.19 | $-0.11 | ||
| Q1 25 | $0.17 | $0.10 | ||
| Q4 24 | $0.20 | $0.38 | ||
| Q3 24 | $0.20 | $-3.11 | ||
| Q2 24 | $0.21 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $653.9M |
| Total Assets | $18.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.3B | $653.9M | ||
| Q4 25 | $2.3B | $693.1M | ||
| Q3 25 | $2.3B | $727.2M | ||
| Q2 25 | $2.2B | $757.8M | ||
| Q1 25 | $2.2B | $798.5M | ||
| Q4 24 | $2.1B | $778.3M | ||
| Q3 24 | $2.2B | $749.6M | ||
| Q2 24 | $2.1B | $879.3M |
| Q1 26 | $18.7B | $1.2B | ||
| Q4 25 | $18.5B | $1.3B | ||
| Q3 25 | $18.5B | $1.3B | ||
| Q2 25 | $18.5B | $1.5B | ||
| Q1 25 | $17.1B | $1.6B | ||
| Q4 24 | $17.1B | $1.6B | ||
| Q3 24 | $17.4B | $1.5B | ||
| Q2 24 | $17.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOPE
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
